ITM Isotopen Technologien Mᅢテᅡᄐnchen AG Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Garching near Munich, Germany
Total Funding:N/A
Industry:Pharma
Founded:2004
Lead Investor(s):N/A

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • ITM Isotopen Technologien Mᅢテᅡᄐnchen AG's estimated annual revenue is currently $23.9M per year.(?)
  • ITM Isotopen Technologien Mᅢテᅡᄐnchen AG's estimated revenue per employee is $201,000

Employee Data

  • ITM Isotopen Technologien Mᅢテᅡᄐnchen AG has 119 Employees.(?)
  • ITM Isotopen Technologien Mᅢテᅡᄐnchen AG grew their employee count by 70% last year.
  • ITM Isotopen Technologien Mᅢテᅡᄐnchen AG currently has 1 job openings.

PASSION FOR PRECISION. ITM Isotopen Technologien Mᅢテᅡᄐnchen AG is a privately held biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclides and -generator platform for a new generation of targeted cancer diagnostics and therapies. ITMᅢᄁ¬ツᆲ¬トᄁs isotope business is profitable and growing. In July 2016 the European Commission has granted Marketing Authorization for EndolucinBetaᅢツᅡᆴ of ITMᅢツᅡᄡs subsidiary ITG Isotope Technologies Garching GmbH. EndolucinBetaᅢツᅡᆴ respectively no-carrier-added (n.c.a.) Lutetium (177Lu) chloride is a radiopharmaceutical precursor and is used in Targeted Radionuclide Therapy. The drug approval is an important milestone for ITM as a specialized radiopharmaceutical company. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine cancers or bone metastases. ITMᅢᄁ¬ツᆲ¬トᄁs main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology. Therapies in Precision Oncology. For more information about ITM, please visit: www.itm.ag Please see our Community Guidelines: https://isotope-technologies-munich.com/service/community-guidelines

keywords:N/A